These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22689689)

  • 1. Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells.
    Pascal V; Laffleur B; Debin A; Cuvillier A; van Egmond M; Drocourt D; Imbertie L; Pangault C; Tarte K; Tiraby G; Cogné M
    Haematologica; 2012 Nov; 97(11):1686-94. PubMed ID: 22689689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
    Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
    J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies.
    Evers M; Ten Broeke T; Jansen JHM; Nederend M; Hamdan F; Reiding KR; Meyer S; Moerer P; Brinkman I; Rösner T; Lebbink RJ; Valerius T; Leusen JHW
    MAbs; 2020; 12(1):1795505. PubMed ID: 32744145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.
    Lohse S; Brunke C; Derer S; Peipp M; Boross P; Kellner C; Beyer T; Dechant M; van der Winkel JG; Leusen JH; Valerius T
    J Biol Chem; 2012 Jul; 287(30):25139-50. PubMed ID: 22679018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
    Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG
    Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.
    Brandsma AM; Ten Broeke T; Nederend M; Meulenbroek LA; van Tetering G; Meyer S; Jansen JH; Beltrán Buitrago MA; Nagelkerke SQ; Németh I; Ubink R; Rouwendal G; Lohse S; Valerius T; Leusen JH; Boross P
    Cancer Immunol Res; 2015 Dec; 3(12):1316-24. PubMed ID: 26407589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.
    Brandsma AM; Bondza S; Evers M; Koutstaal R; Nederend M; Jansen JHM; Rösner T; Valerius T; Leusen JHW; Ten Broeke T
    Front Immunol; 2019; 10():704. PubMed ID: 31031746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
    Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
    Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin A-mediated protection against Bordetella pertussis infection.
    Hellwig SM; van Spriel AB; Schellekens JF; Mooi FR; van de Winkel JG
    Infect Immun; 2001 Aug; 69(8):4846-50. PubMed ID: 11447159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.
    Dechant M; Vidarsson G; Stockmeyer B; Repp R; Glennie MJ; Gramatzki M; van De Winkel JG; Valerius T
    Blood; 2002 Dec; 100(13):4574-80. PubMed ID: 12393717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4.
    van der Steen L; Tuk CW; Bakema JE; Kooij G; Reijerkerk A; Vidarsson G; Bouma G; Kraal G; de Vries HE; Beelen RH; van Egmond M
    Gastroenterology; 2009 Dec; 137(6):2018-29.e1-3. PubMed ID: 19555692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor.
    Dechant M; Beyer T; Schneider-Merck T; Weisner W; Peipp M; van de Winkel JG; Valerius T
    J Immunol; 2007 Sep; 179(5):2936-43. PubMed ID: 17709508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP1 19).
    Shi J; McIntosh RS; Adame-Gallegos J; Dehal PK; van Egmond M; van de Winkel J; Draper SJ; Forbes EK; Corran PH; Holder AA; Woof JM; Pleass RJ
    BMC Biotechnol; 2011 Jul; 11():77. PubMed ID: 21781305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgA EGFR antibodies mediate tumour killing in vivo.
    Boross P; Lohse S; Nederend M; Jansen JH; van Tetering G; Dechant M; Peipp M; Royle L; Liew LP; Boon L; van Rooijen N; Bleeker WK; Parren PW; van de Winkel JG; Valerius T; Leusen JH
    EMBO Mol Med; 2013 Aug; 5(8):1213-26. PubMed ID: 23918228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors.
    Otten MA; Rudolph E; Dechant M; Tuk CW; Reijmers RM; Beelen RH; van de Winkel JG; van Egmond M
    J Immunol; 2005 May; 174(9):5472-80. PubMed ID: 15843545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89).
    van Egmond M; van Spriel AB; Vermeulen H; Huls G; van Garderen E; van de Winkel JG
    Cancer Res; 2001 May; 61(10):4055-60. PubMed ID: 11358825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
    Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
    Front Immunol; 2018; 9():244. PubMed ID: 29651286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
    Engelberts PJ; Voorhorst M; Schuurman J; van Meerten T; Bakker JM; Vink T; Mackus WJ; Breij EC; Derer S; Valerius T; van de Winkel JG; Parren PW; Beurskens FJ
    J Immunol; 2016 Dec; 197(12):4829-4837. PubMed ID: 27807190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells.
    Leung JCK; Tsang AWL; Chan DTM; Lai KN
    J Am Soc Nephrol; 2000 Feb; 11(2):241-249. PubMed ID: 10665931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.